SYMDEKO (COPACKAGED) (Ivacaftor; Ivacaftor, Tezacaftor) Patent Expiration, LOE Window & CMS Spending

SYMDEKO (COPACKAGED) (Ivacaftor; Ivacaftor, Tezacaftor) by Vertex Pharmaceuticals: FDA Orange Book core substance LOE 2035-04-14, 0 AB generics, $0 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorVertex Pharmaceuticals
FDA Application & PathwayN210491 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2035-04-14
Last Listed Patent or Exclusivity Date2035-04-14
Orange Book Patents (*PED Extensions)65 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Vertex Pharmaceuticals across sibling Meru public-data platforms.